International Stem Cell Corporation Completes Enrollment and Dosing in its Parkinson’s Disease Clinical Trial

International Stem Cell Corporation Completes Enrollment and Dosing in its Parkinson’s Disease Clinical Trial

Publication date: Apr 30, 2019

CARLSBAD, Calif. , April 29, 2019 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQX: ISCO) (“ISCO” or “the Company”), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today the completion of subject enrollment in its phase 1 clinical trial of ISC-hpNSC(R) for the treatment of Parkinson’s disease.

The fourth subject of the third cohort, who was the twelfth and final subject of the phase 1 clinical study, was successfully transplanted with the highest dose of ISC-hpNSC(R) cells.

“We are excited to announce the completion of enrollment of the world’s first approved human pluripotent stem cell-based clinical trial for the treatment of Parkinson’s disease.

The goal of this study is to assess the safety and incidence of treatment-emergent adverse events after intracerebral transplantation of 30 million, 50 million, and 70 million ISC-hpNSC(R) cells into the substantia nigra and striatum of patients with Parkinson’s disease.

About ISC-hpNSC(R) International Stem Cell Corporation’s proprietary ISC-hpNSC(R) consists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells.

Preclinical studies in rodents and non-human primates have shown improvement in Parkinson’s disease symptoms and increase in brain dopamine levels following the intracranial administration of ISC-hpNSC(R).

International Stem Cell Corporation believes that ISC-hpNSC(R) may have broad therapeutic applications for many neurological diseases affecting the brain, the spinal cord and the eye.

About International Stem Cell Corporation International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products.

To subscribe to receive ongoing corporate communications, please click on the following link: To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: and Safe harbor statement Statements pertaining to anticipated developments, clinical studies expectations (including timing), resource availability, progress of research and development, and other opportunities for the Company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.

Concepts Keywords
Bank Therapies biomedical products
Biomedical Stage biotechnology
Biotechnology Corporate communications
Brain Cosmetic products
California Stem bank
CARLSBAD Transplantation
Central Nervous System Stem cells
CEO Substantia nigra
CGMP Biotechnology
Clinical Trial Clinical trial
Cohort Psychiatric diagnosis
Control Group RTT
Cosmetic Products Stem cell
Degenerative Disorder Neuron
Dementia Geriatrics
Dopamine Parkinson’s disease
Dopamine Agonists Biotechnology
Dopaminergic Life sciences
Dyskinesia Branches of biology
Eggs Toxicity tumors
Facebook Symptoms disease
Gait Parkinson s disease
Growth Media Parkinsons disease
Homozygous Disease
Immune Rejection Dementia
Incidence Degenerative disorder
Intellectual Property Commercialization potential products
Involuntary Writhing Movements Therapeutic worldwide subsidiary
ISC Clinical placebo control
ISCO
Levodopa
Lifeline
Midbrain
Motor System
Neurological
Neurological Diseases
Neurology
Neurons
Neuroregeneration
Neurotrophic
Oocytes
OTCQX
Parkinson
Parthenogenesis
Parthenogenetic
PhD
Philadelphia
Placebo
Pluripotent
Primates
Royal Melbourne Hospital
Securities Exchange Commission
Skin Care
Spinal Cord
Stem Cell
Stem Cells
Striatum
Substantia Nigra
Symptom
Toxicity
Twitter
Viral

Semantics

Type Source Name
gene UNIPROT CNOT8
gene UNIPROT ANP32B
gene UNIPROT TNFSF13
drug DRUGBANK Nonoxynol-9
gene UNIPROT PDC
gene UNIPROT SSRP1
disease MESH death
drug DRUGBANK Dopamine
disease MESH gait
disease MESH behavioral problems
disease MESH dementia
disease DOID dementia
disease MESH Depression
drug DRUGBANK Levodopa
gene UNIPROT TLR4
disease MESH dyskinesia
disease MESH tumors
disease MESH development
gene UNIPROT BANK1
drug DRUGBANK Coenzyme M

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *